124 related articles for article (PubMed ID: 11094320)
1. Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model.
Hammond LA; Hilsenbeck SG; Eckhardt SG; Marty J; Mangold G; MacDonald JR; Rowinsky EK; Von Hoff DD; Weitman S
Eur J Cancer; 2000 Dec; 36(18):2430-6. PubMed ID: 11094320
[TBL] [Abstract][Full Text] [Related]
2. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
Britten CD; Hilsenbeck SG; Eckhardt SG; Marty J; Mangold G; MacDonald JR; Rowinsky EK; Von Hoff DD; Weitman S
Cancer Res; 1999 Mar; 59(5):1049-53. PubMed ID: 10070962
[TBL] [Abstract][Full Text] [Related]
3. MGI 114: augmentation of antitumor activity when combined with topotecan.
Weitman S; Barrera H; Moore R; Gonzalez C; Marty J; Hilsenbeck S; MacDonald JR; Waters SJ; Von Hoff D
J Pediatr Hematol Oncol; 2000; 22(4):306-14. PubMed ID: 10959900
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft.
Kelner MJ; McMorris TC; Estes L; Samson KM; Bagnell RD; Taetle R
Eur J Cancer; 1998 May; 34(6):908-13. PubMed ID: 9797706
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C.
Kelner MJ; McMorris TC; Rojas RJ; Trani NA; Estes L
Cancer Chemother Pharmacol; 2002 May; 49(5):412-8. PubMed ID: 11976836
[TBL] [Abstract][Full Text] [Related]
6. In vivo antitumour efficacy of MGI-114 (6-hydroxymethylacylfulvene, HMAF) in various human tumour xenograft models including several lung and gastric tumours.
Sato Y; Kashimoto S; MacDonald JR; Nakano K
Eur J Cancer; 2001 Jul; 37(11):1419-28. PubMed ID: 11435075
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents.
Kelner MJ; McMorris TC; Estes L; Wang W; Samson KM; Taetle R
Invest New Drugs; 1996; 14(2):161-7. PubMed ID: 8913837
[TBL] [Abstract][Full Text] [Related]
8. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.
MacDonald JR; Muscoplat CC; Dexter DL; Mangold GL; Chen SF; Kelner MJ; McMorris TC; Von Hoff DD
Cancer Res; 1997 Jan; 57(2):279-83. PubMed ID: 9000568
[TBL] [Abstract][Full Text] [Related]
9. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
Cancer Chemother Pharmacol; 2008 Dec; 63(1):19-26. PubMed ID: 18305940
[TBL] [Abstract][Full Text] [Related]
10. Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan.
Kelner MJ; McMorris TC; Estes L; Samson KM; Trani NA; MacDonald JR
Leukemia; 2000 Jan; 14(1):136-41. PubMed ID: 10637489
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of MGI 114 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft.
Kelner MJ; McMorris TC; Estes LA; Oval MY; Rojas RJ; Lynn JR; Lanham KA; Samson KM
Anticancer Drugs; 2000 Mar; 11(3):217-24. PubMed ID: 10831281
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units.
Hidalgo M; Izbicka E; Eckhardt SG; MacDonald JR; Cerna C; Gomez L; Rowinsky EK; Weitman SD; Von Hoff DD
Anticancer Drugs; 1999 Oct; 10(9):837-44. PubMed ID: 10587294
[TBL] [Abstract][Full Text] [Related]
13. Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft.
Weitman S; Mangold G; Marty J; Dexter D; Hilsenbeck S; Rake J; Juniewicz P; Von Hoff D
Cancer Chemother Pharmacol; 1999; 43(5):402-8. PubMed ID: 10100596
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
Poindessous V; Koeppel F; Raymond E; Cvitkovic E; Waters SJ; Larsen AK
Int J Oncol; 2003 Nov; 23(5):1347-55. PubMed ID: 14532976
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
NĂ©mati F; Daniel C; Arvelo F; Legrier ME; Froget B; Livartowski A; Assayag F; Bourgeois Y; Poupon MF; Decaudin D
Anticancer Drugs; 2010 Jan; 21(1):25-32. PubMed ID: 19823076
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
O'Reilly S; Fleming GF; Barker SD; Walczak JR; Bookman MA; McGuire WP; Schilder RJ; Alvarez RD; Armstrong DK; Horowitz IR; Ozols RF; Rowinsky EK
J Clin Oncol; 1997 Jan; 15(1):177-86. PubMed ID: 8996140
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.
Kaufmann SH; Peereboom D; Buckwalter CA; Svingen PA; Grochow LB; Donehower RC; Rowinsky EK
J Natl Cancer Inst; 1996 Jun; 88(11):734-41. PubMed ID: 8637027
[TBL] [Abstract][Full Text] [Related]
18. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
[TBL] [Abstract][Full Text] [Related]
19. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.
Rowinsky EK; Kaufmann SH; Baker SD; Grochow LB; Chen TL; Peereboom D; Bowling MK; Sartorius SE; Ettinger DS; Forastiere AA; Donehower RC
J Clin Oncol; 1996 Dec; 14(12):3074-84. PubMed ID: 8955652
[TBL] [Abstract][Full Text] [Related]
20. Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan.
Wildner O; Blaese RM; Morris JC
Hum Gene Ther; 1999 Nov; 10(16):2679-87. PubMed ID: 10566896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]